Status:
UNKNOWN
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
Lead Sponsor:
Royal Perth Hospital
Collaborating Sponsors:
The University of Western Australia
Conditions:
Obesity
Hypertension
Eligibility:
All Genders
25-70 years
Phase:
PHASE4
Brief Summary
This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.
Detailed Description
This is a randomised, double-blind, cross-over study. Participants will be randomly assigned to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the alternate treatment. ...
Eligibility Criteria
Inclusion
- Age: 25 -70 years
- (Body Mass Index) BMI≥30kg/m2
- Currently weight stable (+/- 3% in previous 6-12 months and not on any specific exercise or dietary program)
- Elevated clinic systolic (Blood Pressure) BP ≥135 or diastolic BP ≥85mmHg,
- on ACE inhibitor for at least 6 weeks prior to baseline assessment
Exclusion
- Grade 2-3 hypertension (systolic office BP \>160, diastolic office BP \>100 mmHg)
- Secondary causes of hypertension
- CKD (Chronic kidney disease) stage 4-5 {(estimated glomerular filtration) eGFR\<30ml/min}
- Heart failure NYHA (New York Heart Association) class II-IV
- Recent CV (cardiovascular) event (acute myocardial infarction, acute coronary syndrome, stroke or transient ischaemic attack within the previous six months) unstable psychiatric condition
- medication such as corticosteroids, several antidepressants and antipsychotics
- Female participants of childbearing potential must have a negative pregnancy test prior to treatment
Key Trial Info
Start Date :
June 24 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 24 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04474899
Start Date
June 24 2015
End Date
June 24 2024
Last Update
September 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dobney Hypertension Centre
Perth, Western Australia, Australia, 6155